Project description
Optimisation of the personalised medicine approach in ovarian cancer treatment
Personalised medicine (PM) is a novel form of medical care that customises treatment to the disease and the patient. The advantages of this approach are recognised, but its clinical applications are limited due to high complexity and costs. The EU-funded ITHACA project aims to develop a PM platform that involves innovative in-vitro techniques, an advanced computational simulator and standard clinical data for the efficient screening of ovarian cancer therapies and the optimisation of the treatment for each patient. This approach will be validated using standard and primary cell lines to determine the patient-specific therapy outcome in women with ovarian cancer. The results of the project will provide the scientific community with invaluable tools for the further application of PM in the clinic.
Objective
Personalised medicine (PM) is a novel approach to medical care that customises each treatment not just to the disease but also to the patient. While the advantages of this framework are widely recognised and its development is acknowledged as a fundamental societal challenge by the H2020 program, clinical applications are still limited, due to the increased complexity and costs, with respect to the current standard of care. ITHACA aims at developing an innovative PM toolkit that, relying on an advanced computational simulator, innovative in-vitro techniques and standard clinical data could provide an efficient and ethical framework for the screening of different ovarian cancer therapies and the identification of the most effective for each subject. This project builds on my experience with computational modelling and multidisciplinary research environments, to develop a programmable in-silico simulator capable of reproducing the patient-specific response to standard and novel ovarian cancer treatments. This tool will be extensively validated with both standard and primary cell lines and will then be used to determine patient-specific therapy outcome (RECIST 1.1 criteria) in women affected by ovarian cancer. Additionally it will be integrated in a novel bioreactor system for the in-vitro study of metastasization in HGSC. This compound device will allow for automatic treatment optimisation within an accurate and unique experimental model for this disease, and will thus provide an effective platform for personalised treatments development. Funding of this action will be a fundamental opportunity of career development, that will support my training in a highly innovative, interdisciplinary field while fostering the achievement of professional independence. Additionally the results of ITHACA will lead to high profile, impactful publications and provide the scientific community with enabling tools for the extensive application of PM in the clinic.
Fields of science (EuroSciVoc)
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
- medical and health sciences health sciences health care services eHealth
- engineering and technology environmental biotechnology bioremediation bioreactors
- medical and health sciences clinical medicine oncology
You need to log in or register to use this function
We are sorry... an unexpected error occurred during execution.
You need to be authenticated. Your session might have expired.
Thank you for your feedback. You will soon receive an email to confirm the submission. If you have selected to be notified about the reporting status, you will also be contacted when the reporting status will change.
Keywords
Project’s keywords as indicated by the project coordinator. Not to be confused with the EuroSciVoc taxonomy (Fields of science)
Project’s keywords as indicated by the project coordinator. Not to be confused with the EuroSciVoc taxonomy (Fields of science)
Programme(s)
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
-
H2020-EU.1.3. - EXCELLENT SCIENCE - Marie Skłodowska-Curie Actions
MAIN PROGRAMME
See all projects funded under this programme -
H2020-EU.1.3.2. - Nurturing excellence by means of cross-border and cross-sector mobility
See all projects funded under this programme
Topic(s)
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Funding Scheme
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
MSCA-IF - Marie Skłodowska-Curie Individual Fellowships (IF)
See all projects funded under this funding scheme
Call for proposal
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
(opens in new window) H2020-MSCA-IF-2019
See all projects funded under this callCoordinator
Net EU financial contribution. The sum of money that the participant receives, deducted by the EU contribution to its linked third party. It considers the distribution of the EU financial contribution between direct beneficiaries of the project and other types of participants, like third-party participants.
40126 Bologna
Italy
The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.